Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals

JAMA Intern Med. 2015 Dec;175(12):1992-4. doi: 10.1001/jamainternmed.2015.5868.
No abstract available

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Drug Approval / methods*
  • Endpoint Determination
  • Follow-Up Studies
  • Humans
  • United States
  • United States Food and Drug Administration


  • Antineoplastic Agents